ISF154: Tragen began a U.S. dose-ranging Phase II trial of its ISF154 as a monotherapy in 2 cohorts of 20 patients with CLL. In the first cohort, patients refra

Tragen Pharmaceuticals Inc., San Diego, Calif. Product: ISF154 Business: Cancer Therapeutic category: Immune stimulation Target: CD40 receptor on B-cells Description: CD40 agonist Indication: Treat c...